Utility of recombinant proteins LID-1 and PADL in screening for Mycobacterium leprae infection and leprosy

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 108, Issue 8, 2014, Pages 495-501

  de Souza, Marilena Maria ^a   Netto, Eduardo M ^b   Nakatani, Maria ^b   Duthie, Malcolm S ^c  

^a FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Brazil; Diagnosis; Leprosy; Mycobacterium leprae; Serology

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; RECOMBINANT PROTEIN;

ADULT; BRAZIL; FEMALE; HUMAN; IMMUNOLOGY; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PREVALENCE; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BRAZIL; FEMALE; HUMANS; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; PREVALENCE; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84904389424     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru093     Document Type: Article

References (30)

1. WHO. Global Strategy for Further Reducing the Disease Burden due to Leprosy: Plan Period 2011-2015. Geneva: World Health Organization; 2010.
2. Oliveira ML, Cavaliére FA, Maceira JM, Bührer-Sékula S. The use of serology as an additional tool to support diagnosis of difficult multibacillary leprosy cases: lessons from clinical care. Rev Soc Bras Med Trop 2008;41(Suppl 2):27-33.
3. Stefani MM. Challenges in the post genomic era for the development of tests for leprosy diagnosis. Rev Soc Bras Med Trop 2008;41(Suppl 2):89-194.
4. Britton WJ, Lockood DN. Leprosy. Lancet 2004;363:1209-19.
5. Bührer-Sékula S, Visschedijk J, Grossi MA et al. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev 2007;78:70-9.
6. Spencer JS, Kim HJ, WheatWH et al. Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy. Clin Vaccine Immunol 2011;18:260-7.
7. Bührer-Sékula S, Smits HL, Gussenhoven GC et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol 2003;41:1991-5.
8. Hungria EM, Oliveira RM, Souza AL et al. Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil. Mem Inst Oswaldo Cruz. 2012;107(Suppl.1):104-11.
9. Duthie MS, Goto W, Ireton GC et al. Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol 2007;14: 1400-8.
10. Geluk A, Duthie MS, Spencer JS. Postgenomic Mycobacterium leprae antigens for cellular and serological diagnosis of M. leprae exposure, infection and leprosy disease. Lepr Rev 2011;82:402-21.
11. Duthie MS, Hay MN, Morales CZ et al. Rational design and evaluation of a multiepitope chimeric fusion protein with the potential for leprosy diagnosis. Clin Vaccine Immunol 2010;17:298-303.
12. Brazilian Institute of geography and statistics. Cajazeiras indicators, IBGE; 2011. http://cod.ibge.gov.br/232M91 [accessed 30 March 2011].
13. Ministry of Health, Health Surveillance Secretary. Leprosy in Brazil: selected Indicators Brasília-Brazil. Brasília: Ministry of Health; 2009.
14. Ministry of Health, Health Surveillance Secretary. Situation Report-Paraíba. 5th ed. Brasília: Ministry of Health; 2011.
15. Gupte MD, Murthy BN, Mahmood K et al. Application of lot quality assurance sampling for leprosy elimination monitoring-examination of some critical factors. Int J Epidemiol 2008;33:344-8.
16. Moet FJRP, Schuring RP, Pahan D et al. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl Trop Dis 2008;2:e198.
17. Ministry of Health. Notifiable Diseases Information System (SINAN). Epidemiologic Surveillance. Brasília: Cajazeiras Health Secretary; 2012.
18. Ministry of Health, Health Surveillance Secretary. Epidemiologic Surveillance Guide. 6th ed. Brasília: Ministry of Health; 2002.
19. Ministry of Health. Preventing Incapacity Manual Leprosy Prevention and Rehabilitation Books. Brasília: Ministry of Health; 2008.
20. Ministry of Health, Health Surveillance Secretary. Technical Procedure Guide for Baciloscopy in Leprosy. Brasília: Ministry of Health; 2010.
21. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. www.OpenEpi.com 2011. [accessed 25 June 2013].
22. Fletcher RH, Fletcher SW. Clinical epidemiology: the essentials. 4th ed. Baltimore, MD: Wolters, Kluwer, Lippincott, Williams & Wilkins; 2005.
23. World Health Organization. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008;83:293-300.
24. World Health Organization. Global leprosy situation, 2009. Wkly Epidemiol Rec 2009;84:333-40.
25. Bakker MI, Hatta M, Kwenang A et al. Risk factors for developing leprosy-a population-based cohort study in Indonesia. Lepr Rev 2006;7:48-61.
26. Scheureuder PA, Liben DS, Wahjuni S et al. A comparison of rapid Village Survey and Leprosy elimination Campaign, detection methods in two districts of East Java, Indonesia, 1977/1998 and 1999/200. Lep Rev 2002;73:336-75.
27. Duthie MS, Ireton GC, Kanaujia GV et al. Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis. Clin Vaccine Immunol 2008;15:1590-7.
28. Geluk A, Klein MR, Franken KL et al. Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. Infect Immun 2005;73:5636-44.
29. Duthie MS, Truman RW, Goto W et al. Insight toward early diagnosis of leprosy through analysis of the developing antibody responses of Mycobacterium leprae-infected armadillos. Clin Vaccine Immunol 2011;18:254-9.
30. Sampaio LH, Stefani MMA, Oliveira RM et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis 2011;11:26.